HRP20050064A2 - Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase - Google Patents

Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase

Info

Publication number: HRP20050064A2
Authority: HR; Croatia
Prior art keywords: inhibitors; protein kinase; processes; substituted pyrimidines; pyrimidine derivatives
Prior art date: 2002-06-20

Application number

HR20050064A

Other languages

English (en)

Croatian (hr)

Inventor

Charrier Jean-Damien

Mazzei Francesca

Kay David

Miller Andrew

Original Assignee

Vertex Pharmaceuticals Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-20

Filing date

2003-06-19

Publication date

2006-07-31

2003-06-19 Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated

2006-07-31 Publication of HRP20050064A2 publication Critical patent/HRP20050064A2/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

HR20050064A 2002-06-20 2003-06-19 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase HRP20050064A2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39065802P	2002-06-20	2002-06-20
US41160902P	2002-09-18	2002-09-18
PCT/US2003/019266 WO2004000833A1 (en)	2002-06-20	2003-06-19	Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase

Publications (1)

Publication Number	Publication Date
HRP20050064A2 true HRP20050064A2 (en)	2006-07-31

Family

ID=30003168

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20050064A HRP20050064A2 (en)	2002-06-20	2003-06-19	Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase

Country Status (26)

Country	Link
US (4)	US20040049032A1 (no)
EP (4)	EP2277876A1 (no)
JP (5)	JP4237701B2 (no)
KR (2)	KR101141959B1 (no)
CN (1)	CN100484934C (no)
AR (1)	AR040286A1 (no)
AT (2)	ATE556068T1 (no)
AU (1)	AU2003245568B2 (no)
BR (1)	BR0312443A (no)
CA (1)	CA2489824C (no)
CO (1)	CO5680433A2 (no)
DE (1)	DE60336092D1 (no)
EA (2)	EA012869B1 (no)
EC (1)	ECSP055561A (no)
ES (1)	ES2386781T3 (no)
HR (1)	HRP20050064A2 (no)
IL (1)	IL165849A0 (no)
IS (2)	IS7606A (no)
MX (1)	MXPA05000068A (no)
MY (1)	MY141867A (no)
NO (2)	NO331925B1 (no)
NZ (4)	NZ576752A (no)
PL (1)	PL374953A1 (no)
SG (1)	SG170614A1 (no)
TW (2)	TWI354554B (no)
WO (1)	WO2004000833A1 (no)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6660731B2 (en)	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
AU2001296871A1 (en) *	2000-09-15	2002-03-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en)	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
ES2272567T3 (es)	2000-12-21	2007-05-01	Vertex Pharmaceuticals Incorporated	Compuestos de pirazol utiles como inhibidores de proteina quinasas.
WO2003066629A2 (en) *	2002-02-06	2003-08-14	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds useful as inhibitors of gsk-3
WO2003078427A1 (en)	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azolylaminoazines as inhibitors of protein kinases
MY141867A (en) *	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
EA200500299A1 (ru)	2002-08-02	2005-08-25	Вертекс Фармасьютикалз Инкорпорейтед	Пиразольные композиции, используемые в качестве ингибиторов gsk-3
US7601718B2 (en) *	2003-02-06	2009-10-13	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
EP1694671A2 (en) *	2003-12-04	2006-08-30	Vertex Pharmaceuticals Incorporated	Quinoxalines useful as inhibitors of protein kinases
EP1694686A1 (en) *	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Kinase inhibitors
JP2007522233A (ja)	2004-02-11	2007-08-09	アムジエン・インコーポレーテツド	バニロイド受容体リガンド及び治療におけるそれらの使用
KR20070011458A (ko)	2004-04-08	2007-01-24	탈자진 인코포레이티드	키나제의 벤조트리아진 억제제
US20050250829A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Kinase inhibitors
JP2008510734A (ja) *	2004-08-18	2008-04-10	タケダサンディエゴインコーポレイテッド	キナーゼ阻害剤
NZ588896A (en)	2004-08-25	2012-05-25	Targegen Inc	Heterocyclic compounds and methods of use
AR050948A1 (es)	2004-09-24	2006-12-06	Hoffmann La Roche	Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US7285569B2 (en)	2004-09-24	2007-10-23	Hoff Hoffmann-La Roche Inc.	Tricycles, their manufacture and use as pharmaceutical agents
US7713973B2 (en)	2004-10-15	2010-05-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
CA2587427A1 (en)	2004-11-17	2006-05-26	Miikana Therapeutics, Inc.	Kinase inhibitors
EP1841760B1 (en)	2004-12-30	2011-08-10	Exelixis, Inc.	Pyrimidine derivatives as kinase modulators and method of use
JP2008535876A (ja)	2005-04-14	2008-09-04	エフ．ホフマン−ラロシュアーゲー	アミノピラゾール誘導体、これらの製造、及び医薬製剤としての使用。
US20060281788A1 (en) *	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US7825244B2 (en) *	2005-06-10	2010-11-02	Janssen Pharmaceutica Nv	Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US20060281768A1 (en) *	2005-06-10	2006-12-14	Gaul Michael D	Thienopyrimidine and thienopyridine kinase modulators
US8071768B2 (en) *	2005-06-10	2011-12-06	Janssen Pharmaceutica, N.V.	Alkylquinoline and alkylquinazoline kinase modulators
EP1906967A4 (en) *	2005-07-26	2010-07-28	Vertex Pharma	ABL Kinase Inhibition
EP1917259B1 (en) *	2005-08-18	2012-01-25	Vertex Pharmaceuticals Incorporated	Pyrazine kinase inhibitors
EP1928456B1 (en) *	2005-09-30	2015-04-22	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
US8119655B2 (en) *	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
WO2007048088A2 (en)	2005-10-18	2007-04-26	Janssen Pharmaceutica N.V.	Method of inhibiting flt3 kinase
AU2006309013B2 (en)	2005-11-01	2012-06-28	Impact Biomedicines, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
AU2013201630B2 (en) *	2005-11-03	2016-12-01	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
TW200736250A (en) *	2005-11-03	2007-10-01	Vertex Pharma	Aminopyrimidines useful as kinase inhibitors
DE602006021776D1 (de) *	2005-11-16	2011-06-16	Vertex Pharma	Als kinaseinhibitoren geeignete aminopyrimidine
EP1968950A4 (en) *	2005-12-19	2010-04-28	Genentech Inc	PYRIMIDINKINASEINHIBITOREN
US7560551B2 (en)	2006-01-23	2009-07-14	Amgen Inc.	Aurora kinase modulators and method of use
HRP20160039T1 (hr)	2006-01-23	2016-02-12	Amgen, Inc	Modulatori aurora kinaze i postupak uporabe
US20090062302A1 (en) *	2006-01-24	2009-03-05	Buser-Doepner Carolyn A	Jak2 Tyrosine Kinase Inhibition
US7868177B2 (en)	2006-02-24	2011-01-11	Amgen Inc.	Multi-cyclic compounds and method of use
AR059898A1 (es)	2006-03-15	2008-05-07	Janssen Pharmaceutica Nv	Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US8697716B2 (en) *	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
BRPI0710548B8 (pt)	2006-04-20	2021-05-25	Janssen Pharmaceutica Nv	inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
JP5089681B2 (ja) *	2006-04-20	2012-12-05	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ｃ−ｆｍｓキナーゼの阻害剤としての複素環式化合物
US7615627B2 (en)	2006-06-21	2009-11-10	Reliance Life Sciences Pvt. Ltd.	RNA interference mediated inhibition of aurorakinase B and its combinations as anticancer therapy
EP2043651A2 (en)	2006-07-05	2009-04-08	Exelixis, Inc.	Methods of using igf1r and abl kinase modulators
GB0619343D0 (en) *	2006-09-30	2006-11-08	Vernalis R&D Ltd	New chemical compounds
EA200970361A1 (ru)	2006-10-09	2010-02-26	Такеда Фармасьютикал Компани Лимитед	Ингибиторы киназы
EP2223925A1 (en) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Kinase inhibitors
JP5528807B2 (ja)	2006-10-12	2014-06-25	アステックス、セラピューティックス、リミテッド	複合薬剤
US8916552B2 (en)	2006-10-12	2014-12-23	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008057280A1 (en)	2006-10-27	2008-05-15	Amgen Inc.	Multi-cyclic compounds and methods of use
WO2008057940A1 (en) *	2006-11-02	2008-05-15	Vertex Pharmaceuticals Incorporated	Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
JP2010513567A (ja) *	2006-12-19	2010-04-30	バーテックスファーマシューティカルズインコーポレイテッド	プロテインキナーゼの阻害剤として有用なアミノピリミジン
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JP5520057B2 (ja) *	2007-03-09	2014-06-11	バーテックスファーマシューティカルズインコーポレイテッド	蛋白キナーゼの阻害剤として有用なアミノピリミジン
CA2679701A1 (en)	2007-03-09	2008-09-18	Vertex Pharmaceuticals Incorporated	Aminopyridines useful as inhibitors of protein kinases
KR20090120510A (ko) *	2007-03-09	2009-11-24	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 아미노피리미딘
CA2682195A1 (en) *	2007-03-20	2008-09-25	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
EP2137177B1 (en)	2007-04-05	2014-05-07	Amgen, Inc	Aurora kinase modulators and method of use
EP2146982A2 (en) *	2007-04-13	2010-01-27	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
CA2688584A1 (en) *	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
WO2008137621A1 (en) *	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
CA2685876A1 (en)	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Thiazoles and pyrazoles useful as kinase inhibitors
CN101687852A (zh) *	2007-05-24	2010-03-31	沃泰克斯药物股份有限公司	可用作激酶抑制剂的噻唑类和吡唑类化合物
CA2683152A1 (en) *	2007-06-11	2008-12-18	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
WO2009018415A1 (en)	2007-07-31	2009-02-05	Vertex Pharmaceuticals Incorporated	Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
CN103342695B (zh)	2007-09-14	2015-04-22	杨森制药有限公司	1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
EP2205565B1 (en)	2007-09-14	2013-04-17	Janssen Pharmaceuticals, Inc.	1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
CA2697399C (en)	2007-09-14	2016-01-19	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
JO3240B1 (ar) *	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
RU2492170C9 (ru)	2007-11-14	2013-12-27	Орто-Макнейл-Янссен Фармасьютикалз, Инк.	Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
WO2009065232A1 (en) *	2007-11-20	2009-05-28	University Health Network	Cancer diagnostic and therapeutic methods that target plk4/sak
WO2009073224A1 (en) *	2007-12-07	2009-06-11	Ambit Biosciences Corp.	Methods of treating certain diseases using pyrimidine derivatives
WO2009086012A1 (en) *	2007-12-20	2009-07-09	Curis, Inc.	Aurora inhibitors containing a zinc binding moiety
CA2716856C (en)	2008-03-20	2013-02-19	Amgen Inc.	Aurora kinase modulators and method of use
US9126935B2 (en)	2008-08-14	2015-09-08	Amgen Inc.	Aurora kinase modulators and methods of use
ES2439291T3 (es)	2008-09-02	2014-01-22	Janssen Pharmaceuticals, Inc.	Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
MX2011002312A (es) *	2008-09-03	2011-04-26	Vertex Pharma	Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
NZ603495A (en) *	2008-09-05	2014-05-30	Celgene Avilomics Res Inc	Algorithm for designing irreversible inhibitors
EP2346505B1 (en)	2008-10-16	2014-04-23	Janssen Pharmaceuticals, Inc.	Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
AR074210A1 (es)	2008-11-24	2010-12-29	Boehringer Ingelheim Int	Derivados de pirimidina como inhibidores de ptk2-quinasa
ES2401691T3 (es)	2008-11-28	2013-04-23	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
EP2376082B1 (en)	2008-12-22	2014-03-05	Millennium Pharmaceuticals, Inc.	Combination of aurora kinase inhibitors and anti-cd20 antibodies
SG176021A1 (en)	2009-05-12	2011-12-29	Janssen Pharmaceuticals Inc	1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
BRPI1010831A2 (pt)	2009-05-12	2016-04-05	Addex Pharmaceuticals Sa	derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN105063001A (zh) *	2009-09-16	2015-11-18	新基阿维罗米克斯研究公司	蛋白激酶复合物和含有该复合物的药物组合物以及它们的用途
JP2013516422A (ja)	2009-12-30	2013-05-13	アビラセラピューティクス，インコーポレイテッド	タンパク質のリガンド−指向性共有的修飾
WO2012059932A1 (en)	2010-11-01	2012-05-10	Aurigene Discovery Technologies Limited	2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
AU2010363329A1 (en)	2010-11-07	2013-05-09	Targegen, Inc.	Compositions and methods for treating myelofibrosis
EP2643320B1 (en)	2010-11-08	2015-03-04	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298809B (zh)	2010-11-08	2016-08-31	杨森制药公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2814996C (en)	2010-11-08	2019-10-01	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US9382229B2 (en) *	2011-02-15	2016-07-05	The Johns Hopkins University	Compounds and methods of use thereof for treating neurodegenerative disorders
CN104024246B (zh) *	2012-03-27	2016-03-02	广东东阳光药业有限公司	作为欧若拉激酶抑制剂的取代嘧啶衍生物
NZ700928A (en)	2012-04-24	2017-06-30	Vertex Pharma	Dna-pk inhibitors
EP2852388A4 (en)	2012-05-23	2016-01-13	Univ Johns Hopkins	COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CN104870438A (zh) *	2012-06-07	2015-08-26	佐治亚州立大学研究基金会公司	Seca抑制剂以及其制备和使用方法
ES2608628T3 (es)	2012-08-07	2017-04-12	Janssen Pharmaceutica Nv	Procedimiento para la preparacion de derivados de ester heterociclicos
JOP20180012A1 (ar)	2012-08-07	2019-01-30	Janssen Pharmaceutica Nv	عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
TWI569799B (zh)	2012-09-21	2017-02-11	安羅格製藥股份有限公司	抑制組成型活性磷酸化ｆｌｔ３激酶的方法
EP2914265A4 (en) *	2012-11-05	2016-04-13	Nant Holdings Ip Llc	SUBSTITUTED INDOL-5-OL COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS
CN103202843B (zh) *	2012-12-31	2015-04-29	刘强	一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
BR112015016282A2 (pt)	2013-01-07	2017-07-11	Arog Pharmaceuticals Inc	crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
WO2014134776A1 (en)	2013-03-04	2014-09-12	Merck Sharp & Dohme Corp.	Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) *	2013-03-04	2014-09-12	Merck Sharp & Dohme Corp.	Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9440952B2 (en)	2013-03-04	2016-09-13	Merck Sharp & Dohme Corp.	Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134774A1 (en)	2013-03-04	2014-09-12	Merck Sharp & Dohme Corp.	Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP2970218B8 (en)	2013-03-12	2019-04-10	Vertex Pharmaceuticals Incorporated	Dna-pk inhibitors
RU2017141536A (ru) *	2013-03-15	2019-02-13	Нэнтбайосайенс, Инк.	Замещенные производные индол-5-ола и их терапевтические применения
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
SI3057953T1 (sl)	2013-10-17	2018-12-31	Vertex Pharmaceuticals Incorporated	Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk
US10463658B2 (en)	2013-10-25	2019-11-05	Videra Pharmaceuticals, Llc	Method of inhibiting FLT3 kinase
EP3076963A4 (en)	2013-12-06	2017-09-13	Millennium Pharmaceuticals, Inc.	Combination of aurora kinase inhibitors and anti-cd30 antibodies
HRP20191646T1 (hr)	2014-01-21	2019-12-13	Janssen Pharmaceutica Nv	Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba
SMT202100103T1 (it)	2014-01-21	2021-03-15	Janssen Pharmaceutica Nv	Combinazione comprendente modulatori allosterici postivi del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
JP6434530B2 (ja) *	2014-10-30	2018-12-05	富士フイルム株式会社	有機アミン塩及びその製造方法、並びに、アゾ色素の製造方法
US10752612B2 (en)	2015-04-17	2020-08-25	Ludwig Institute For Cancer Research Ltd	PLK4 inhibitors
EP3324976A4 (en)	2015-07-21	2019-03-27	Millennium Pharmaceuticals, Inc.	ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
WO2017210545A1 (en)	2016-06-02	2017-12-07	Cadent Therapeutics, Inc.	Potassium channel modulators
WO2018064092A1 (en)	2016-09-27	2018-04-05	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
JP2019532011A (ja)	2016-11-02	2019-11-07	アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
MX376080B (es)	2017-01-23	2025-03-07	Novartis Ag	Moduladores del canal de potasio
CN108250191B (zh) *	2018-03-15	2020-10-20	兰州大学	一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用
US11874276B2 (en)	2018-04-05	2024-01-16	Dana-Farber Cancer Institute, Inc.	STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es)	2018-09-09	2020-03-12	Fundacio Privada Institut De Recerca De La Sida - Caixa	Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
BR112021007552A2 (pt)	2018-10-22	2021-07-27	Cadent Therapeutics, Inc.	formas cristalinas de moduladores de canal de potássio
US20220305048A1 (en)	2019-08-26	2022-09-29	Dana-Farber Cancer Institute, Inc.	Use of heparin to promote type 1 interferon signaling
US11969420B2 (en)	2020-10-30	2024-04-30	Arog Pharmaceuticals, Inc.	Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
JP2025511697A (ja)	2022-04-07	2025-04-16	イーライリリーアンドカンパニー	Ｋｒａｓｇ１２ｃ阻害剤を作製するための方法
WO2023196887A1 (en)	2022-04-08	2023-10-12	Eli Lilly And Company	Method of treatment including kras g12c inhibitors and aurora a inhibitors
EP4547251A1 (en)	2022-06-30	2025-05-07	Eli Lilly and Company	Kras g12c inhibitor for treating cancer

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3133081A (en) *		1964-05-12		J-aminoindazole derivatives
US3935183A (en) *	1970-01-26	1976-01-27	Imperial Chemical Industries Limited	Indazole-azo phenyl compounds
BE754242A (fr) *	1970-07-15	1971-02-01	Geigy Ag J R	Diamino-s-triazines et dinitro-s-triazines
US3939183A (en) *	1973-10-05	1976-02-17	Chevron Research Company	Purification of maleic anhydride
US3998951A (en) *	1974-03-13	1976-12-21	Fmc Corporation	Substituted 2-arylquinazolines as fungicides
GB1446126A (en)	1974-05-16	1976-08-18	Res Inst For Medicine Chemistr	Photolytic preparation of diol mononitrates
DE2458965C3 (de) *	1974-12-13	1979-10-11	Bayer Ag, 5090 Leverkusen	3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
MA18829A1 (fr)	1979-05-18	1980-12-31	Ciba Geigy Ag	Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DE2922436A1 (de)	1979-06-01	1980-12-18	Sueddeutsche Kalkstickstoff	Verfahren zur gewinnung von harnstoffkoernern mit verbesserten eigenschaften
DOP1981004033A (es) *	1980-12-23	1990-12-29	Ciba Geigy Ag	Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
SE8102194L (sv) *	1981-04-06	1982-10-07	Pharmacia Ab	Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
SE8102193L (sv) *	1981-04-06	1982-10-07	Pharmacia Ab	Terapeutiskt aktiv organisk forening och dess anvendning
JPS58124773A (ja) *	1982-01-20	1983-07-25	Mitsui Toatsu Chem Inc	５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤
US4477450A (en) *	1983-03-03	1984-10-16	Riker Laboratories, Inc.	Triazolo [4,3-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
EP0136976A3 (de)	1983-08-23	1985-05-15	Ciba-Geigy Ag	Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
NO157836C (no)	1985-04-19	1988-05-25	Jacobsen As J	Anordning ved asymmetrisk belysning.
DE3725638A1 (de)	1987-08-03	1989-02-16	Bayer Ag	Neue aryloxy (bzw. thio)aminopyrimidine
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5597920A (en)	1992-04-30	1997-01-28	Neurogen Corporation	Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
JPH0665237A (ja)	1992-05-07	1994-03-08	Nissan Chem Ind Ltd	置換ピラゾール誘導体および農園芸用殺菌剤
HU212308B (en) *	1992-06-09	1996-05-28	Richter Gedeon Vegyeszet	Process for producing novel pregnane steroids and pharmaceutical compositions containing the same
ES2262137T3 (es)	1993-10-01	2006-11-16	Novartis Ag	Derivados de pirimidinamina farmacologicamente activos y procedimientos para su preparacion.
CA2203517A1 (en)	1994-11-10	1996-05-23	Alan M. Laibelman	Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
IL117659A (en) *	1995-04-13	2000-12-06	Dainippon Pharmaceutical Co	Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
CA2230896A1 (en)	1995-09-01	1997-03-13	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en)	1995-09-01	1999-08-10	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
US6716575B2 (en) *	1995-12-18	2004-04-06	Sugen, Inc.	Diagnosis and treatment of AUR1 and/or AUR2 related disorders
ATE227283T1 (de)	1996-07-13	2002-11-15	Glaxo Group Ltd	Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
JPH10130150A (ja)	1996-09-05	1998-05-19	Dainippon Pharmaceut Co Ltd	酢酸アミド誘導体からなる医薬
GB9619284D0 (en) *	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
JP4205168B2 (ja)	1996-10-02	2009-01-07	ノバルティスアクチエンゲゼルシヤフト	ピリミジン誘導体およびその製造法
JP2001506974A (ja)	1996-10-11	2001-05-29	ワーナー―ランバート・コンパニー	インターロイキン―１β変換酵素のアスパルテートエステル阻害剤
CA2306692C (en)	1997-10-10	2010-09-21	Cytovia, Inc.	Dipeptide apoptosis inhibitors and the use thereof
US6267952B1 (en) *	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
JP2000026421A (ja)	1998-01-29	2000-01-25	Kumiai Chem Ind Co Ltd	ジアリ―ルスルフィド誘導体及び有害生物防除剤
BR9908004A (pt) *	1998-02-17	2001-12-18	Tularik Inc	Composto, composição e método para prevençãoou supressão de uma infecção viral
DE69925268T2 (de)	1998-03-16	2006-03-23	Cytovia, Inc., San Diego	Dipeptid-Caspase-Inhibitoren und deren Verwendung
NZ508314A (en)	1998-06-02	2004-03-26	Osi Pharm Inc	Pyrrolo[2,3d]pyrimidine compositions and their use
US6489344B1 (en)	1998-06-19	2002-12-03	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
EP1105394A1 (en) *	1998-08-21	2001-06-13	Du Pont Pharmaceuticals Company	ISOXAZOLO 4,5-d]PYRIMIDINES AS CRF ANTAGONISTS
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
ES2241324T3 (es)	1998-10-08	2005-10-16	Astrazeneca Ab	Derivados de quinazolina.
GB9828640D0 (en)	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
GB9828511D0 (en) *	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
CN1149204C (zh)	1999-01-13	2004-05-12	沃尼尔·朗伯公司	1-杂环取代的二芳基胺
ES2265929T3 (es)	1999-03-30	2007-03-01	Novartis Ag	Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
JP2003502424A (ja)	1999-06-17	2003-01-21	シオノギバイオリサーチコーポレイション	Ｉｌ−１２産生の阻害物質
GB9914258D0 (en) *	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
MY133159A (en)	1999-08-13	2007-10-31	Vertex Pharma	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1218360B1 (en)	1999-10-07	2008-05-28	Amgen Inc.,	Triazine kinase inhibitors
JP3955468B2 (ja)	1999-11-30	2007-08-08	ファイザー・プロダクツ・インク	免疫抑制薬として有用な２，４−ジアミノピリミジン化合物
PT1246623E (pt)	1999-12-02	2006-12-29	Osi Pharm Inc	Compostos específicos para o receptor de adenosina a1,a2a e a3 e as suas utilizações
US6376489B1 (en)	1999-12-23	2002-04-23	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
MY125768A (en)	1999-12-15	2006-08-30	Bristol Myers Squibb Co	N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
EP1246823A1 (en) *	1999-12-28	2002-10-09	Pharmacopeia, Inc.	Pyrimidine and triazine kinase inhibitors
US20020065270A1 (en) *	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
EP1200422A2 (en) *	2000-02-05	2002-05-02	Vertex Pharmaceuticals Incorporated	Pyrazole compositions useful as inhibitors of erk
AU2001237041B9 (en)	2000-02-17	2005-07-28	Amgen Inc.	Kinase inhibitors
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
EP1268519B1 (en)	2000-04-03	2005-06-15	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2001079198A1 (en)	2000-04-18	2001-10-25	Agouron Pharmaceuticals, Inc.	Pyrazoles for inhibiting protein kinase
CA2407231A1 (en) *	2000-04-28	2002-10-23	Tanabe Seiyaku Co., Ltd.	Cyclic compounds
PL360439A1 (en) *	2000-06-28	2004-09-06	Astrazeneca Ab	Substituted quinazoline derivatives and their use as inhibitors
CA2410662C (en)	2000-07-21	2012-09-18	Schering Corporation	Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
OA12368A (en)	2000-08-31	2004-04-13	Pfizer Prod Inc	Pyrazole derivatives and their use as protein kinase inhibitors.
US6613776B2 (en) *	2000-09-15	2003-09-02	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
EP1317453B1 (en) *	2000-09-15	2006-08-09	Vertex Pharmaceuticals Incorporated	Isoxazoles and their use as inhibitors of erk
AU2001296871A1 (en) *	2000-09-15	2002-03-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) *	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) *	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
EP1318984A1 (en)	2000-09-20	2003-06-18	MERCK PATENT GmbH	4-amino-quinazolines
US6641579B1 (en) *	2000-09-29	2003-11-04	Spectrasonics Imaging, Inc.	Apparatus and method for ablating cardiac tissue
DE10061863A1 (de) *	2000-12-12	2002-06-13	Basf Ag	Verfahren zur Herstellung von Triethylendiamin (TEDA)
US6716851B2 (en) *	2000-12-12	2004-04-06	Cytovia, Inc.	Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (en)	2000-12-12	2005-06-22	Cytovia Inc	SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
ES2272567T3 (es)	2000-12-21	2007-05-01	Vertex Pharmaceuticals Incorporated	Compuestos de pirazol utiles como inhibidores de proteina quinasas.
MY130778A (en) *	2001-02-09	2007-07-31	Vertex Pharma	Heterocyclic inhibitiors of erk2 and uses thereof
US6949544B2 (en) *	2001-03-29	2005-09-27	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
WO2002083667A2 (en) *	2001-04-13	2002-10-24	Vertex Pharmaceuticals Incorporated	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1383771A1 (en) *	2001-04-20	2004-01-28	Vertex Pharmaceuticals Incorporated	9-deazaguanine derivatives as inhibitors of gsk-3
AU2002308748A1 (en) *	2001-05-16	2002-11-25	Vertex Pharmaceuticals Incorporated	Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
MXPA03011652A (es) *	2001-06-15	2004-05-31	Vertex Pharma	5-(2-aminopirimidin-4-il) benzioxazoles como inhibidores de proteinas cinasa.
JP4342937B2 (ja) *	2001-07-03	2009-10-14	バーテックスファーマシューティカルズインコーポレイテッド	ＳｒｃおよびＬｃｋタンパク質キナーゼの阻害剤としてのイソキサゾールピリミジン
WO2003026664A1 (en)	2001-09-26	2003-04-03	Bayer Corporation	2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US6569499B2 (en) *	2001-10-02	2003-05-27	Xerox Corporation	Apparatus and method for coating photoreceptor substrates
WO2003049739A1 (en) *	2001-12-07	2003-06-19	Vertex Pharmaceuticals, Inc.	Pyrimidine-based compounds useful as gsk-3 inhibitors
WO2003078427A1 (en) *	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azolylaminoazines as inhibitors of protein kinases
ATE365733T1 (de) *	2002-03-15	2007-07-15	Vertex Pharma	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
WO2003077921A1 (en) *	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azinylaminoazoles as inhibitors of protein kinases
US7179826B2 (en) *	2002-03-15	2007-02-20	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
US20030207873A1 (en) *	2002-04-10	2003-11-06	Edmund Harrington	Inhibitors of Src and other protein kinases
AU2003237121A1 (en) *	2002-04-26	2003-11-10	Vertex Pharmaceuticals Incorporated	Pyrrole derivatives as inhibitors of erk2 and uses thereof
MY141867A (en)	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
WO2004005283A1 (en) *	2002-07-09	2004-01-15	Vertex Pharmaceuticals Incorporated	Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
EA200500299A1 (ru)	2002-08-02	2005-08-25	Вертекс Фармасьютикалз Инкорпорейтед	Пиразольные композиции, используемые в качестве ингибиторов gsk-3
EP1928456B1 (en)	2005-09-30	2015-04-22	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
JP2010513567A (ja)	2006-12-19	2010-04-30	バーテックスファーマシューティカルズインコーポレイテッド	プロテインキナーゼの阻害剤として有用なアミノピリミジン

2003
- 2003-06-16 MY MYPI20032232A patent/MY141867A/en unknown
- 2003-06-18 US US10/464,430 patent/US20040049032A1/en not_active Abandoned
- 2003-06-19 MX MXPA05000068A patent/MXPA05000068A/es unknown
- 2003-06-19 DE DE60336092T patent/DE60336092D1/de not_active Expired - Lifetime
- 2003-06-19 AT AT03739195T patent/ATE556068T1/de active
- 2003-06-19 EP EP10182211A patent/EP2277876A1/en not_active Withdrawn
- 2003-06-19 ES ES03739195T patent/ES2386781T3/es not_active Expired - Lifetime
- 2003-06-19 EP EP03739195A patent/EP1517905B1/en not_active Expired - Lifetime
- 2003-06-19 NZ NZ576752A patent/NZ576752A/en not_active IP Right Cessation
- 2003-06-19 CA CA2489824A patent/CA2489824C/en not_active Expired - Fee Related
- 2003-06-19 BR BR0312443-6A patent/BR0312443A/pt not_active IP Right Cessation
- 2003-06-19 HR HR20050064A patent/HRP20050064A2/xx not_active Application Discontinuation
- 2003-06-19 AT AT06020384T patent/ATE498621T1/de not_active IP Right Cessation
- 2003-06-19 EA EA200500053A patent/EA012869B1/ru not_active IP Right Cessation
- 2003-06-19 EP EP10183009A patent/EP2292614A1/en not_active Withdrawn
- 2003-06-19 AU AU2003245568A patent/AU2003245568B2/en not_active Ceased
- 2003-06-19 KR KR1020107028539A patent/KR101141959B1/ko not_active Expired - Fee Related
- 2003-06-19 KR KR1020047020794A patent/KR101067254B1/ko not_active Expired - Fee Related
- 2003-06-19 JP JP2004515904A patent/JP4237701B2/ja not_active Expired - Fee Related
- 2003-06-19 AR ARP030102187A patent/AR040286A1/es unknown
- 2003-06-19 NZ NZ562953A patent/NZ562953A/en not_active IP Right Cessation
- 2003-06-19 WO PCT/US2003/019266 patent/WO2004000833A1/en active Application Filing
- 2003-06-19 NZ NZ549142A patent/NZ549142A/en unknown
- 2003-06-19 CN CNB038188880A patent/CN100484934C/zh not_active Expired - Fee Related
- 2003-06-19 NZ NZ537720A patent/NZ537720A/en not_active IP Right Cessation
- 2003-06-19 EA EA200801372A patent/EA015990B1/ru not_active IP Right Cessation
- 2003-06-19 SG SG200608886-8A patent/SG170614A1/en unknown
- 2003-06-19 EP EP06020384A patent/EP1746093B1/en not_active Expired - Lifetime
- 2003-06-19 PL PL03374953A patent/PL374953A1/xx unknown
- 2003-06-20 TW TW092116828A patent/TWI354554B/zh not_active IP Right Cessation
- 2003-06-20 TW TW096112205A patent/TWI297684B/zh not_active IP Right Cessation
2004
- 2004-12-19 IL IL16584904A patent/IL165849A0/xx unknown
- 2004-12-20 IS IS7606A patent/IS7606A/is unknown
2005
- 2005-01-11 NO NO20050144A patent/NO331925B1/no not_active IP Right Cessation
- 2005-01-20 EC EC2005005561A patent/ECSP055561A/es unknown
- 2005-01-20 CO CO05004362A patent/CO5680433A2/es not_active Application Discontinuation
- 2005-01-21 IS IS7661A patent/IS7661A/is unknown
- 2005-07-21 JP JP2005211959A patent/JP4662823B2/ja not_active Expired - Fee Related
2006
- 2006-08-09 US US11/500,981 patent/US7557106B2/en not_active Expired - Fee Related
2009
- 2009-05-06 US US12/436,407 patent/US8268829B2/en not_active Expired - Fee Related
2010
- 2010-06-23 JP JP2010143227A patent/JP2010202673A/ja not_active Withdrawn
- 2010-06-23 JP JP2010143228A patent/JP2010235626A/ja not_active Withdrawn
2011
- 2011-04-05 NO NO20110523A patent/NO20110523L/no unknown
2012
- 2012-08-15 US US13/585,861 patent/US8779127B2/en not_active Expired - Fee Related
2014
- 2014-03-14 JP JP2014051076A patent/JP2014111662A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP1746093B1 (en)	2011-02-16
JP2006501176A (ja)	2006-01-12
EA012869B1 (ru)	2009-12-30
DE60336092D1 (de)	2011-03-31
EP2277876A1 (en)	2011-01-26
TW200406210A (en)	2004-05-01
EP1517905A1 (en)	2005-03-30
AU2003245568A1 (en)	2004-01-06
NO20110523L (no)	2005-03-21
MY141867A (en)	2010-07-16
US20060270660A1 (en)	2006-11-30
MXPA05000068A (es)	2005-04-11
EA200500053A1 (ru)	2005-08-25
CA2489824A1 (en)	2003-12-31
CO5680433A2 (es)	2006-09-29
IS7606A (is)	2004-12-20
US7557106B2 (en)	2009-07-07
AU2003245568B2 (en)	2009-12-17
US20130066069A1 (en)	2013-03-14
JP4662823B2 (ja)	2011-03-30
AR040286A1 (es)	2005-03-23
ATE498621T1 (de)	2011-03-15
PL374953A1 (en)	2005-11-14
NO20050144L (no)	2005-03-21
NZ576752A (en)	2010-11-26
HK1081178A1 (zh)	2006-05-12
KR101067254B1 (ko)	2011-09-27
US8779127B2 (en)	2014-07-15
KR101141959B1 (ko)	2012-05-04
ECSP055561A (es)	2005-03-10
TWI297684B (en)	2008-06-11
US20040049032A1 (en)	2004-03-11
TW200736231A (en)	2007-10-01
JP2014111662A (ja)	2014-06-19
NO331925B1 (no)	2012-05-07
HK1077057A1 (en)	2006-02-03
NZ537720A (en)	2007-01-26
JP2010235626A (ja)	2010-10-21
JP2010202673A (ja)	2010-09-16
ES2386781T3 (es)	2012-08-30
BR0312443A (pt)	2005-05-10
EP1517905B1 (en)	2012-05-02
EA015990B1 (ru)	2012-01-30
KR20050009756A (ko)	2005-01-25
SG170614A1 (en)	2011-05-30
NZ549142A (en)	2008-04-30
CA2489824C (en)	2011-05-03
CN100484934C (zh)	2009-05-06
JP2005320351A (ja)	2005-11-17
US8268829B2 (en)	2012-09-18
NZ562953A (en)	2009-06-26
EP2292614A1 (en)	2011-03-09
JP4237701B2 (ja)	2009-03-11
US20090221602A1 (en)	2009-09-03
NO20050144D0 (no)	2005-01-11
KR20110010794A (ko)	2011-02-07
EA200801372A1 (ru)	2008-08-29
CN1675199A (zh)	2005-09-28
IL165849A0 (en)	2006-01-15
ATE556068T1 (de)	2012-05-15
WO2004000833A1 (en)	2003-12-31
HK1100081A1 (en)	2007-09-07
EP1746093A1 (en)	2007-01-24
IS7661A (is)	2005-01-21
TWI354554B (en)	2011-12-21

Publication	Publication Date	Title
HRP20050064A2 (en)	2006-07-31	Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase
EA200500721A1 (ru)	2005-12-29	Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
NO20062174L (no)	2006-07-14	Sulfoksiminsubstituerte pyrimidiner for anvendelse som CDK og /eller VEGF-inhibitorer, fremstilling derav og deres anvendelse som legemidler
WO2003106416A3 (en)	2004-05-06	CHEMICAL PROCESS
ATE190978T1 (de)	2000-04-15	6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung
WO2004030620A3 (en)	2004-06-10	Novel tyrosine kinase inhibitors
DE60316013D1 (de)	2007-10-11	Heteroaryl-pyrimidinderivate als jak-inhibitoren
TN2009000128A1 (en)	2010-10-18	Dihydropyridine derivatives useful as protein kinase inhibitors
BRPI0406809A (pt)	2005-12-27	Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
DE60314500D1 (de)	2007-08-02	Diaminopyrimidine und deren verwendung als angiogenesehemmer
NO20062020L (no)	2006-07-10	1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
RS20050769A (en)	2007-11-15	Derivatives of 2-acylamino-4- phenylthiazole,preparation method thereof and application of same in therapeutics
BR9709443B1 (pt)	2009-05-05	n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
DE602004014117D1 (de)	2008-07-10	Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE417051T1 (de)	2008-12-15	Polymorphe von clopidogrel-hydrogensulfat
ZA200609637B (en)	2008-08-27	4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
NO20050514L (no)	2005-03-18	Sammensetning og antiviral aktivitet til substituerte azaindoloksoeddikpiperazinderivater
UA85394C2 (ru)	2009-01-26	Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
WO2005076990A3 (en)	2005-11-24	Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
ATE347555T1 (de)	2006-12-15	6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
NO20080418L (no)	2008-03-28	Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme
WO2005076854A3 (en)	2005-12-22	Pyrimidinone compounds useful as kinase inhibitors
DE50201565D1 (de)	2004-12-23	2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
DE60213802D1 (de)	2006-09-21	Cak inhibitoren und deren verwendungen
WO2004034985A3 (en)	2004-09-10	Chemical compounds

Legal Events

Date	Code	Title	Description
2006-07-31	A1OB	Publication of a patent application
2007-01-19	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2012-06-06	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20120606 Year of fee payment: 10
2013-11-07	ODBI	Application refused